Azurity Pharmaceuticals, Inc., a privately held company committed to delivering innovative, high-quality medicines, announced that the US Food and Drug Administration (FDA) has approved Xifyrm (meloxicam injection) an IV non-steroidal anti-inflammatory drug (NSAID) that offers once daily dosing.
• Xifyrm is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.
• Xifyrm provides a non-opioid analgesic in a 30mg/mL vial for IV bolus injection over 15 seconds.
• Because of delayed onset of analgesia, Xifyrm alone is not recommended for use when rapid onset of analgesia is required.
• “Xifyrm demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management,” said Ron Scarboro, CEO at Azurity Pharmaceuticals.
• “Xifyrm addresses an important clinical need, especially for patients requiring a non-opioid component to multimodal analgesia strategies.”
Xifyrm will be available in the coming weeks.
• Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients.
• Azurity’s global footprint is over 50 countries, with a diversified portfolio of 30+ marketed brands spanning ten dosage forms and ten key therapeutic areas.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!